Designation of Denosumab (XGEVA) as an Orphan Drug - Amgen Australia Pty Ltd

Overview

The designation of denosumab (XGEVA) as an orphan drug under the Therapeutic Goods Regulations 1990 represents a significant step in addressing the treatment needs of patients with rare conditions. Enacted by the Australian Parliament, this legislative measure was introduced to encourage the development of treatments for rare diseases, which often receive limited attention from pharmaceutical companies due to the smaller patient population. The policy objective behind this designation is to provide incentives for the development of orphan drugs, thereby ensuring that patients with rare diseases have access to potentially life-saving treatments. The designation was issued by Dr. Anthony Gill, the Delegate of the Secretary, on 3 October 2012, under the authority granted by subregulation 16J(2) of the Regulations, specifically for the treatment of giant cell tumours of the bone. This action by Amgen Australia Pty Ltd, the sponsor of denosumab (XGEVA), highlights a commitment to addressing unmet medical needs and advancing therapeutic options for rare diseases in Australia.

Scope and Application

The Designation of denosumab (XGEVA) as an orphan drug under the Therapeutic Goods Regulations 1990 applies specifically to the pharmaceutical product denosumab, marketed as XGEVA, which is designated for the treatment of patients with giant cell tumours of the bone. This designation is effective as of 3rd October 2012 and was made by Dr Anthony Gill, who is acting as the Delegate of the Secretary. The Regulations, which form part of the legislative framework under the Therapeutic Goods Act 1989, provide the authority for such designations to encourage the research, development, and availability of treatments for rare diseases or conditions. The application of this designation is limited to the specific indication and dose form mentioned, which is solution for injection. The sponsor of the drug, Amgen Australia Pty Ltd, is responsible for ensuring compliance with the conditions of the designation. While the primary focus is on orphan drug status, the geographic reach of the designation is inherently tied to Australia, as the Therapeutic Goods Regulations apply nationally within Australia. The legislation does not specify any exclusions, exemptions, or thresholds other than those related to the orphan drug criteria and the specific indication for denosumab. Any further application or extension of the scope through subordinate instruments would need to comply with the overarching provisions of the Therapeutic Goods Regulations.

Key Provisions

The main operative sections of this legislation pertain to the designation of denosumab (XGEVA) as an orphan drug for the treatment of patients with giant cell tumours of the bone. According to section 1, Dr. Anthony Gill, acting as the Delegate of the Secretary under subregulation 16J(2) of the Therapeutic Goods Regulations 1990, made this designation on 3rd October 2012. The drug, in its solution for injection form, is specified for this particular medical condition (sections 1 and 2). The sponsor of denosumab (XGEVA) is identified as Amgen Australia Pty Ltd (section 3). The obligations and requirements imposed by this Act on the parties involved are primarily centred around the designation and approval process for orphan drugs. Dr. Anthony Gill, in his capacity as the Delegate of the Secretary, must ensure that the drug meets the criteria for orphan drug designation under the Therapeutic Goods Regulations 1990. This includes verifying that the drug is intended for the treatment of a rare disease or condition, in this case, giant cell tumours of the bone, and that it has been appropriately developed and tested. The sponsor, Amgen Australia Pty Ltd, must also ensure that they comply with all relevant regulations and provide necessary information and documentation to support the orphan drug designation. There are no explicit offences, penalties, or civil/criminal consequences detailed in the text of this legislation for breaches related to orphan drug designation. However, any failure to comply with the Therapeutic Goods Regulations 1990, including those pertaining to the designation and marketing of orphan drugs, could potentially lead to regulatory action by the Therapeutic Goods Administration (TGA). Such actions may include fines, product recalls, or other enforcement measures. The maximum penalties for breaches of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can vary widely depending on the nature and severity of the offence, and can include substantial fines and/or imprisonment. It is important for all parties involved to adhere to the requirements set forth in the legislation and the regulations to avoid any potential consequences.